drugset
drugset / Trial / NCT02752243

CIK-Cells in Relapsing Patients With Acute Leukemia or Myelodysplastic Syndromes After SCT.

NCT02752243 ↗

Phase 1/2 Unknown 32 enrolled Peter Bader
NaSingle-groupOpen-labelTreatment

Summary

Multi-site, non-randomized Phase I/II study involving children and adults.

Timeline

Start
2016-03
Primary completion
2023-03
Completion
2024-03

Drugs

EvaluationDrugModalityDoseRoute
Subject CIK cells Cell therapy — —

Indications

acute leukemia myelodysplastic syndrome